Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma
pharmaceutical investing Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Goldera Provides Update on 2026 Exploration Programs Targeting Multiple Gold Discovery Opportunities in Ontario and New Brunswick
Nevgold Files NI 43-101 Technical Report For Mineral Resource Estimate on the Limousine Butte Gold-Antimony Project, Nevada
